GSTM1 and anemia: We also recorded an increase in bleeding events in patients taking antiplatelet drugs as compared to those not on antiplatelets (13% versus 6.7%; RR 2.4, 95%CI 0.8 to 6.0; log-rank test p < 0.05; Figure 2); a similar result was found in patients with a history of previous bleeding than in those without (40.0% versus 6.2%; RR 8.8, 95% CI 3.0 to 32.3; log-rank test p < 0.001; Figure 3) and in patients with anemia at baseline (Hb < 110 mg/L) versus those without (22.7% versus 6.5%; RR 3.8, 95% CI 1.2 to 10.2; log-rank test p = 0.004).